ProQR Therapeutics NV
NASDAQ:PRQR
Intrinsic Value
ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amauros... [ Read More ]
The intrinsic value of one
PRQR
stock under the Base Case scenario is
2.94
USD.
Compared to the current market price of 1.94 USD,
ProQR Therapeutics NV
is
Undervalued by 34%.
ProQR Therapeutics NV's market capitalization is 163.4m USD.
PRQR stock price is 1.94 USD.
PRQR stock price (1.94 USD) is 34% less than its Intrinsic Value (2.94 USD).
PRQR. Open DCF Valuation
PRQR has upside potential of 122% compared to the average analyst price target.
Open Wall St Estimates
PRQR's Revenue has been growing by 0% per year for the last 3 years.
PRQR's long-term assets (138m EUR) exceed its long-term liabilties (96m EUR).
PRQR's Revenue is forecast to grow at a rate of 17% per year over the next 3 years.
PRQR's ROE (Return on Equity) has significantly increased in the last 3 years from -66% to -53%, and is approaching profitability.
PRQR's Revenue has grown by an exceptional 98% over the past 12 months.
PRQR's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -269% to -68%, and is approaching profitability.
PRQR has negative Operating Income for the last twelve months.
PRQR has negative Net Income for the last twelve months.
PRQR's ROE (Return on Equity) for the past 12 months is negative and is equal to -53%.
PRQR's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -68%.
PRQR's D/E (Debt to Equity) is very low and is equal to 0.44.
PRQR has positive Free Cash Flow for the last twelve months.
PRQR's short-term assets (121m EUR) exceed its short-term liabilties (34m EUR).
PRQR has negative three-year average ROE (Return on Equity): -66%. The company is not efficient at transforming stockholders' equity into net income.
PRQR has negative three-year average ROIC (Return on Invested Capital): -235%. The company is not efficient at using invested capital to generate operating income.
PRQR has negative Net Debt. This means that the company has more cash and short-term investments (119m EUR) than debt (18m EUR).
PRQR's Altman Z-Score is very low and is equal to -4.01.
PRQR doesn't generate enough operating income (-32m EUR) to safely cover interest payments on its debt (789k EUR).
Valuation Backtest
ProQR Therapeutics NV
Run backtest to discover the historical profit from buying and selling
PRQR
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
ProQR Therapeutics NV
Balance Sheet Decomposition
ProQR Therapeutics NV
| Current Assets | 121m |
| Cash & Short-Term Investments | 118.9m |
| Receivables | 745k |
| Other Current Assets | 1.3m |
| Non-Current Assets | 16.9m |
| PP&E | 16.9m |
| Current Liabilities | 34.2m |
| Accounts Payable | 1.5m |
| Accrued Liabilities | 1.7m |
| Other Current Liabilities | 31m |
| Non-Current Liabilities | 62.3m |
| Long-Term Debt | 18.1m |
| Other Non-Current Liabilities | 44.2m |
Earnings Waterfall
ProQR Therapeutics NV
|
Revenue
|
9.5m
EUR
|
|
Operating Expenses
|
-41.4m
EUR
|
|
Operating Income
|
-31.9m
EUR
|
|
Other Expenses
|
3.7m
EUR
|
|
Net Income
|
-28.1m
EUR
|
Free Cash Flow Analysis
ProQR Therapeutics NV
PRQR Profitability Score
Profitability Due Diligence
ProQR Therapeutics NV's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
ProQR Therapeutics NV's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
PRQR Solvency Score
Solvency Due Diligence
ProQR Therapeutics NV's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
ProQR Therapeutics NV's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PRQR Price Targets Summary
ProQR Therapeutics NV
According to Wall Street analysts, the average 1-year price target for
PRQR
is 4.3 USD
with a low forecast of 1.82 USD and a high forecast of 6.3 USD.
Shareholder Return
PRQR Price
ProQR Therapeutics NV
| Average Annual Return | -8.13% |
| Standard Deviation of Annual Returns | 72.24% |
| Max Drawdown | -96% |
| Market Capitalization | 163.4m USD |
| Shares Outstanding | 81 354 600 |
| Percentage of Shares Shorted | 0.45% |
Company Profile
ProQR Therapeutics NV
Country
Industry
Market Cap
Dividend Yield
Description
ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. The company is headquartered in Leiden, Zuid-Holland. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. The company designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
Contact
IPO
Employees
Officers
The intrinsic value of one
PRQR
stock under the Base Case scenario is
2.94
USD.
Compared to the current market price of 1.94 USD,
ProQR Therapeutics NV
is
Undervalued by 34%.
You don't have any saved screeners yet
